Episode description
After a lull which has now picked up with FDA approvals, what's next for renal denervation? RQM+ VP of Intelligence and Innovation Jaishankar Kutty, Ph.D. shares the knowns and unknowns in a new video clip.
📝 Quick summary
Renal denervation is a technology that aims to control blood pressure by disrupting renal nerve activity through a minimally invasive, irreversible procedure. Clinical trial data is mixed, with modest reductions in blood pressure observed. Skepticism and uncertainties surround the technology due to risks, lack of markers for procedural success, and unclear durability of benefits.
The post-market phase is crucial for generating more data and addressing unanswered questions. Patient population and risk-stratified benefit-risk analysis are important considerations, and a clinical outcomes study is needed to evaluate the impact of renal denervation on cardiovascular events.
💭 Takeaways
- The state of play and the adjunctive nature of renal denervation in treating resistant hypertension in some patients.
- Strong focus on what’s lacking from a benefit-risk perspective today and what needs to be studied in the post-market phase.
🕒 Timestamps
00:00 Introduction and Background
01:26 Renal Denervation as a Therapy for Hypertension
02:25 Technology and Procedure of Renal Denervation
03:21 Clinical Trials and Efficacy of Renal Denervation
04:46 Skepticism and Uncertainties Surrounding Renal Denervation
06:15 Post-Market Phase and Expectations
07:41 Challenges and Questions for Renal Denervation
08:58 Patient Population and Benefit-Risk Analysis
10:15 Risks and Modest Benefits of Renal Denervation
10:44 Need for Clinical Outcomes Study
11:14 Conclusion
-
📹 View and share this clip on LinkedIn.
📲 Follow RQM+ on LinkedIn.
📚 See on-demand content in our Knowledge Center.
📝 If you'd like to speak with us directly about how we might be able to support you and your organization, you're welcome to use our contact form.